SS Innovations Gains Regulatory Approvals for Surgical Robot in Four New Markets
Event summary
- SS Innovations received regulatory approval for its SSi Mantra surgical robotic system in Colombia, Oman, Sri Lanka, and Kenya.
- Approvals were granted by INVIMA (Colombia), DGPA&DC (Oman), NMRA (Sri Lanka), and PPB (Kenya) between November 2025 and January 2026.
- The SSi Mantra has now been approved in 11 countries, with a cumulative installed base of 168 units and 7,885 surgeries performed as of December 2025.
- The company anticipates FDA 510(k) clearance in the U.S. by mid-2026 and EU CE marking certification later in 2026.
The big picture
SS Innovations is strategically expanding into emerging markets with its cost-effective surgical robotic system, targeting regions with limited access to advanced robotic surgery. The company's focus on affordability and ease of use positions it to compete with higher-cost alternatives in both developed and developing markets. Success in these new regions could drive significant revenue growth, particularly if the company secures regulatory approvals in the U.S. and Europe.
What we're watching
- Market Penetration
- How SS Innovations will leverage its cost advantages to gain traction in underpenetrated markets like Colombia and Kenya.
- Regulatory Progress
- Whether the company can secure FDA and EU approvals as projected, which would significantly expand its addressable market.
- Competitive Positioning
- The pace at which SS Innovations can differentiate itself from established players in the surgical robotics space.